Over 3 million people in the United States are living with chronic hepatitis C viral (HCV) infection. Psychiatric illnesses are considered a barrier to achieving sustained virological response (SVR) in patients with HCV but early detection and treatment of depression can improve antiviral adherence. Depressive disorder is a commonly existing comorbidity of HCV, with an estimated prevalence of 14%. Insomnia is associated with specific direct-acting antivirals (DAAs), requiring treatment for some during the 12-24 weeks of treatment and post-treatment surveillance. Psychiatric pharmacists can help improve adherence with antiviral medications by concomitantly managing psychiatric symptoms and monitoring symptom response. In addition to performing baseline psychiatric evaluations and managing interferon-induced psychiatric symptoms, psychiatric pharmacists should provide patient education on HCV and the antiviral medications, and manage drug-drug interactions prior to initiating DAAs.
These tables/tools can be used as part of the training for psychiatric pharmacists to perform the basic duties of a clinical hepatic pharmacist, while influencing psychiatric care for patients infected with HCV who require antiviral treatment.
For additional information on the medications and HCV-related tools and calculators, please go to Hepatitis C Online.
This toolkit was authored by CPNP member Susie H. Park, PharmD, BCPP, FCSHP. It has been adapted from a resource original created for the CPNP 2018 session A Complicated Relationship: Depression, Insomnia, and Hepatitis C. That ACPE-accredited session will be available online until April 2021.
CPNP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.